Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 4/20 | 0.53 |
| ▸ | HTR6 | P50406 | 3/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | DRD3 | P35462 | 2/20 | 0.49 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.49 |
| ▸ | HTR3B | O95264 | 2/20 | 0.49 |
| ▸ | HTR3A | P46098 | 2/20 | 0.49 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.49 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 3/20 | 0.48 |
| ▸ | HTR2A | P28223 | 3/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTR5A | P47898 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38664325 | 0.83 | ADRB1 (0.59) | ADRB1HTR6DRD2DRD3HTR3E | |
| SCHEMBL630979 | 0.83 | ADRB1 (0.59) | ADRB1HTR6DRD2DRD3HTR3E | |
| Hydrochloric Acid SCHEMBL631231 | 0.81 | ADRB1 (0.58) | ADRB1HTR6DRD2DRD3HTR3E | |
| SCHEMBL5340480 | 0.80 | ADRB1 (0.56) | ADRB1HTR6DRD2DRD3HTR3E | |
| SCHEMBL231778 | 0.76 | EPHX2 (0.61) | ADRB1HTR6DRD2DRD3HTR3E | |
| SCHEMBL29831977 | 0.76 | EPHX2 (0.61) | ADRB1HTR6DRD2DRD3HTR3E | |
| Hydrochloric Acid SCHEMBL16400334 | 0.75 | EPHX2 (0.59) | ADRB1HTR6HTR3EHTR3BHTR3A | |
| SCHEMBL15834279 | 0.74 | ADRB1 (0.75) | ADRB1HTR6DRD2DRD3HTR3E | |
| SCHEMBL31561598 | 0.74 | HTR1A (0.73) | ADRB1HTR6DRD2DRD3HTR3E | |
| SCHEMBL335802 | 0.74 | HTR1A (0.73) | ADRB1HTR6DRD2DRD3HTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10968179-B2 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20200290953-A1 | Charged Ion Channel Blockers and Methods for Use | Nocion Therapeutics, Inc. | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200290953-A1 | Charged Ion Channel Blockers and Methods for Use | TRPV1, TRPV2, TRPV5 | ADRB1 250/4885HTR6 2010/4885DRD2 2772/4885 |
| US-10968179-B2 | Charged ion channel blockers and methods for use | TRPV1, TRPV2, TRPV5 | ADRB1 250/4885HTR6 2010/4885DRD2 2772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.